Economic evaluation of Varicella vaccination: results of a systematic review

References

• Epicentro: Il portale dell'epidemiologia per la sanità pubblica. Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute. Available at: http://www.epicentro.iss.it/problemi/varicella/varicella.asp; last access 19.11.12.
   Google Scholar
• Presidente del Consiglio dei Ministri. D.P.C.M. Definizione dei livelli essenziali di assistenza. G.U.8 Febbraio 2002, n.33, S.
   Google Scholar
• Institut RK. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2006. Epidemiol Bull 2006; 30:235 - 54
   Google Scholar
• Childhood immunisation calendar, Greece. Available at: http://www.mohaw.gr/gr/thefuture/anakoinoseis/Timetable%202008.xls
   Google Scholar
• Macartney KK, Burgess MA. Varicella vaccination in Australia and New Zealand. J Infect Dis 2008; 197:Suppl 2 S191 - 5; http://dx.doi.org/10.1086/522157; PMID: 18419396
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization. National Advisory Committee on Immunization (NACI) update on varicella. Can Commun Dis Rep 2004; 30:1 - 26; PMID: 14964716
   PubMedGoogle Scholar
• Sadzot-Delvaux C, Rentier B, Wutzler P, Asano Y, Suga S, Yoshikawa T, et al. Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis 2008; 197:Suppl 2 S185 - 90; http://dx.doi.org/10.1086/522163; PMID: 18419395
   PubMedGoogle Scholar
• WHO vaccine preventable disease monitoring system: Immunization schedules by antigen, selection centre. Available at: http/www.who.int/immunization_monitoring/en/globalsummary/scheduleselect.cfm
   Google Scholar
• Marin M, Güris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:RR-4 1 - 40; PMID: 17585291
   PubMedGoogle Scholar
• Alfonsi V, D’Ancona F, Giambi C, Nacca G, Rota MC, Regional Coordinators for Infectious Diseases and Vaccinations. Current immunization policies for pneumococcal, meningococcal C, varicella and rotavirus vaccinations in Italy. Health Policy 2011; 103:176 - 83; http://dx.doi.org/10.1016/j.healthpol.2011.10.002; PMID: 22030308
   PubMed Web of Science ®Google Scholar
• Bernaola Iturbe E, Giménez Sánchez F, Baca Cots M, de Juan Martín F, Díez Domingo J, Garcés Sánchez M, et al, Spanish Association of Pediatrics. [Vaccination schedule of the Spanish Association of Pediatrics: recommendations 2007]. An Pediatr (Barc) 2007; 66:62 - 9; PMID: 17266854
   PubMedGoogle Scholar
• Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J 2007; 26:153 - 8; http://dx.doi.org/10.1097/01.inf.0000250689.09396.21; PMID: 17259879
   PubMed Web of Science ®Google Scholar
• Bonanni P, Breuer J, Gershon A, Gershon M, Hryniewicz W, Papaevangelou V, et al. Varicella vaccination in Europe - taking the practical approach. BMC Med 2009; 7:26; http://dx.doi.org/10.1186/1741-7015-7-26; PMID: 19476611
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Vazquez M, Esposito D, Holabird N, Steinberg SP, Dziura J, et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis 2011; 203:312 - 5; http://dx.doi.org/10.1093/infdis/jiq052; PMID: 21208922
   PubMed Web of Science ®Google Scholar
• Kattan JA, Sosa LE, Bohnwagner HD, Hadler JL. Impact of 2-dose vaccination on varicella epidemiology: Connecticut--2005-2008. J Infect Dis 2011; 203:509 - 12; http://dx.doi.org/10.1093/infdis/jiq081; PMID: 21199882
   PubMed Web of Science ®Google Scholar
• Committee on Infectious Diseases. Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics 2011; 128:630 - 2; http://dx.doi.org/10.1542/peds.2011-1968; PMID: 21873692
   PubMed Web of Science ®Google Scholar
• Gruppo di lavoro ICONA. ICONA 2008: Indagine di Copertura vaccinale Nazionale nei bambini e negli adolescenti. Rapporti ISTISAN 09/29. Istituto Superiore di Sanità, Roma; 2009.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among children aged 19-35 months--United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:689 - 96; PMID: 22951450
   PubMedGoogle Scholar
• Ward K, Dey A, Hull B, Quinn HE, Macartney K, Menzies R. Evaluation of Australia’s varicella vaccination program for children and adolescents. Vaccine 2013; 31:1413 - 9; http://dx.doi.org/10.1016/j.vaccine.2012.12.052; PMID: 23290837
   PubMed Web of Science ®Google Scholar
• Ozaki T. Varicella vaccination in Japan: necessity of implementing a routine vaccination program. J Infect Chemother 2013; 19:188 - 95; http://dx.doi.org/10.1007/s10156-013-0577-x; PMID: 23483311
   PubMed Web of Science ®Google Scholar
• Piano Nazionale Prevenzione vaccinale 2012-2014. Ministero della salute. Available at: http://www.salute.gov.it/dettaglio/phPrimoPianoNew.jsp?id=339; last access 19.11.12.
   Google Scholar
• Scuffham P, Devlin N, Eberhart-Phillips J, Wilson-Salt R. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Soc Sci Med 1999; 49:763 - 79; http://dx.doi.org/10.1016/S0277-9536(99)00115-X; PMID: 10459888
   PubMed Web of Science ®Google Scholar
• Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 1999; 18:407 - 15; http://dx.doi.org/10.1016/S0264-410X(99)00261-3; PMID: 10519929
   PubMed Web of Science ®Google Scholar
• Díez Domingo J, Ridao M, Latour J, Ballester A, Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 1999; 17:1306 - 11; http://dx.doi.org/10.1016/S0264-410X(98)00394-6; PMID: 10195765
   PubMed Web of Science ®Google Scholar
• Coudeville L, Paree F, Lebrun T, Sailly JC. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999; 17:142 - 51; http://dx.doi.org/10.1016/S0264-410X(98)00161-3; PMID: 9987148
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002; 20:1113 - 25; http://dx.doi.org/10.1016/S0264-410X(01)00437-6; PMID: 11803072
   PubMed Web of Science ®Google Scholar
• Wutzler P, Neiss A, Banz K, Goertz A, Bisanz H. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany. Med Microbiol Immunol 2002; 191:89 - 96; http://dx.doi.org/10.1007/s00430-002-0123-4; PMID: 12410347
   PubMed Web of Science ®Google Scholar
• Getsios D, Caro JJ, Caro G, De Wals P, Law BJ, Robert Y, et al. Instituting a routine varicella vaccination program in Canada: an economic evaluation. Pediatr Infect Dis J 2002; 21:542 - 7; http://dx.doi.org/10.1097/00006454-200206000-00012; PMID: 12182379
   PubMed Web of Science ®Google Scholar
• Hsu HC, Lin RS, Tung TH, Chen TH. Cost-benefit analysis of routine childhood vaccination against chickenpox in Taiwan: decision from different perspectives. Vaccine 2003; 21:3982 - 7; http://dx.doi.org/10.1016/S0264-410X(03)00270-6; PMID: 12922134
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 2003; 88:862 - 9; http://dx.doi.org/10.1136/adc.88.10.862; PMID: 14500303
   PubMed Web of Science ®Google Scholar
• Banz K, Wagenpfeil S, Neiss A, Goertz A, Staginnus U, Vollmar J, et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 2003; 21:1256 - 67; http://dx.doi.org/10.1016/S0264-410X(02)00431-0; PMID: 12559807
   PubMed Web of Science ®Google Scholar
• Hanslik T, Boëlle PY, Schwarzinger M, Carrat F, Freedberg KA, Valleron AJ, et al. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine 2003; 21:3614 - 22; http://dx.doi.org/10.1016/S0264-410X(03)00405-5; PMID: 12922090
   PubMed Web of Science ®Google Scholar
• Thiry N, Beutels P, Tancredi F, Romanò L, Zanetti A, Bonanni P, et al. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine 2004; 22:3546 - 62; http://dx.doi.org/10.1016/j.vaccine.2004.03.043; PMID: 15315834
   PubMed Web of Science ®Google Scholar
• Ginsberg GM, Somekh E. Cost containment analysis of childhood vaccination against varicella in Israel. J Infect 2004; 48:119 - 33; http://dx.doi.org/10.1016/S0163-4453(03)00079-3; PMID: 14720487
   PubMed Web of Science ®Google Scholar
• Jean-Jasmin LM, Lynette SP, Stefan M, Kai CS, Chew FT, Wah LB. Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination. Southeast Asian J Trop Med Public Health 2004; 35:693 - 6; PMID: 15689089
   PubMedGoogle Scholar
• Coudeville L, Brunot A, Giaquinto C, Lucioni C, Dervaux B. Varicella vaccination in Italy : an economic evaluation of different scenarios. Pharmacoeconomics 2004; 22:839 - 55; http://dx.doi.org/10.2165/00019053-200422130-00003; PMID: 15329030
   PubMed Web of Science ®Google Scholar
• Tseng HF, Tan HF, Chang CK. Varicella epidemiology and cost-effectiveness analysis of universal varicella vaccination program in Taiwan. Southeast Asian J Trop Med Public Health 2005; 36:1450 - 8; PMID: 16610647
   PubMedGoogle Scholar
• Coudeville L, Brunot A, Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value Health 2005; 8:209 - 22; http://dx.doi.org/10.1111/j.1524-4733.2005.04005.x; PMID: 15877593
   PubMed Web of Science ®Google Scholar
• Lenne X, Diez Domingo J, Gil A, Ridao M, Lluch JA, Dervaux B. Economic evaluation of varicella vaccination in Spain: results from a dynamic model. Vaccine 2006; 24:6980 - 9; http://dx.doi.org/10.1016/j.vaccine.2006.04.051; PMID: 16860909
   PubMed Web of Science ®Google Scholar
• Hammerschmidt T, Bisanz H, Wutzler P. Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis. Vaccine 2007; 25:7307 - 12; http://dx.doi.org/10.1016/j.vaccine.2007.08.017; PMID: 17881097
   PubMed Web of Science ®Google Scholar
• Valentim J, Sartori AMC, de Soárez PC, Amaku M, Azevedo RS, Novaes HM. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil. Vaccine 2008; 26:6281 - 91; http://dx.doi.org/10.1016/j.vaccine.2008.07.021; PMID: 18674582
   PubMed Web of Science ®Google Scholar
• Zhou F, Ortega-Sanchez IR, Guris D, Shefer A, Lieu T, Seward JF. An economic analysis of the universal varicella vaccination program in the United States. J Infect Dis 2008; 197:Suppl 2 S156 - 64; http://dx.doi.org/10.1086/522135; PMID: 18419391
   PubMed Web of Science ®Google Scholar
• Bonanni P, Boccalini S, Bechini A, Banz K. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases. Vaccine 2008; 26:5619 - 26; http://dx.doi.org/10.1016/j.vaccine.2008.07.096; PMID: 18723062
   PubMed Web of Science ®Google Scholar
• Banz K, Iseli A, Aebi C, Brunner M, Schmutz AM, Heininger U. Economic evaluation of varicella vaccination in Swiss children and adolescents. Hum Vaccin 2009; 5:847 - 57; PMID: 19829048
   PubMed Web of Science ®Google Scholar
• Bonanni P. Italie-la politique de vaccination. Vax Info 2003; 36:6 - 8
   Google Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Int J Public Health 2009; 4:94 - 131
   Google Scholar
• Drummond MF, Jefferson TO, The BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313:275 - 83; http://dx.doi.org/10.1136/bmj.313.7052.275; PMID: 8704542
   PubMed Web of Science ®Google Scholar
• La Torre G, Nicolotti N, de Waure C, Ricciardi W. Development of a weighted scale to assess the quality of cost-effectiveness studies and an application to the economic evaluations of tetravalent HPV vaccine. Int J Public Health 2011; 19:103 - 11; http://dx.doi.org/10.1007/s10389-010-0377-z
   Google Scholar